UK: Abbott v Edwards Lifesciences – Getting To The Heart Of Interim Injunctions In Patent Litigation

Last Updated: 17 June 2019
Article by Brian Whitehead

The judgment of Henry Carr J in Abbott v Edwards Lifesciences, whilst breaking no new ground in legal terms, provides a useful illustration of the English courts' approach to applications for interim injunctions in patent cases.

The dispute concerns medical devices for treating mitral regurgitation, which "is a life-threatening condition in which the mitral valve of the heart ceases to function properly". The patentee, Abbott, markets a product called MitraClip, which is implanted into the mitral valve. Although the UK market for the device is currently very small, because the implant procedure is not presently funded by the NHS, the NHS is currently considering whether to fund the procedure, in which case of course the market will expand. Edwards has developed its own device, which it intends to launch under the name PASCAL. Edwards' intention is to roll out PASCAL in a small number of hospitals between October 2019 and February 2020, with a controlled roll-out to continue thereafter until the end of June 2020. Abbott has commenced patent infringement proceedings, and applied for an interim injunction against Edwards.

Interim injunction applications are governed by the so-called American Cyanamid principles, as follows:

The court does not generally carry out a detailed analysis of the merits of the underlying case. Provided the court is satisfied that there is a serious issue to be tried, the court proceeds to the next step.

The court asks whether there is a likelihood that the claimant, if denied an interim injunction, will suffer irreparable or unquantifiable harm i.e. harm that cannot be compensated in damages.

The court then asks whether, in the event that an interim injunction is granted and the claimant subsequently fails at trial, the defendant is likely to suffer irreparable or unquantifiable harm i.e. harm that cannot be compensated under the cross-undertaking in damages which the claimant is required to provide.

If there is a likelihood of irreparable or unquantifiable harm to both parties, the court carries out a balancing exercise, determining which course of action (granting or withholding the interim injunction) seems likely to cause the least irremediable prejudice to one party or the other.

In carrying out that balancing exercise, the court can take into account factors other than irreparable harm. Preservation of the status quo can be an important factor, as can be (in appropriate cases) public interest. Less commonly, the court may take into account the apparent strength of the parties' cases, although that is a more exceptional factor.

It was common ground between the parties that there was a serious issue to be tried, and the judge was not therefore required to look at the merits of the claim (or the counterclaim for revocation). In addressing the issue of likelihood to irreparable harm to Abbott, a matter of key relevance was the fact that Abbott had already obtained an order for an expedited trial. Clearly, the shorter the period between an interim injunction hearing and trial, the lower is the likelihood of irreparable harm occurring. Specifically, the claim was commenced at the end of January 2019, and the trial will take place in December 2019, with judgment expected by the end of January 2020. The injunction hearing took place at the beginning of May 2019, and consequently the court had to consider whether there was a likelihood of irreparable harm in the approximately nine month period until judgment. The nature of the activities proposed by Edwards in that nine month was also of key relevance. As the judge put it, "A full-scale launch pending trial would raise different considerations from a controlled testing of the market". Edwards gave an undertaking that it would do no more than implant PASCAL devices in 10 patients in 2 UK hospitals. Given that limited activity, the judge held that damages could easily be quantified following trial, on a one-for-one lost sale basis.

The claimant marshalled a number of alternative arguments in support of its irreparable harm argument, including the risk of cross-selling, risk of disrupting Abbott's relationships with clinicians and the risk of brand damage to Abbott. The judge rejected each of those arguments. Of particular interest is the judge's rejection of Abbott's argument based on Edwards' failure to clear the way of patents before deciding to launch PASCAL. There is a long-standing principle in English patent law that it is desirable for a party, seeking to launch a product, to identify and "clear the way" (whether by a revocation action or by an application for a declaration of non-infringement) of potentially relevant third party patents. A failure to clear the way has been held to be a factor in favour of an interim injunction being granted. The judge examined the rationale of that principle, holding that "failure to clear the way is a material factor in cases where irreparable harm to both parties is evenly balanced". Where, as in this instance, no likelihood of irreparable harm to the claimant can be demonstrated, a failure to clear the way is simply an irrelevant factor.

Given the judge's findings as to lack of irreparable harm to Abbott, it was not strictly necessary for him to consider the next American Cyanamid question – likelihood of irreparable harm to Edwards. However, the judge did consider that question, in case he was held on appeal to be wrong in relation to the first question. The judge held that if Edwards was injuncted, it would be unable to compete with Abbott when (as the parties expect) the NHS agrees to fund the implantation of mitral valve implants. The effect of that inability, at the outset of an expanding market, would be difficult to quantify in financial terms. Consequently, the judge held that even if (contrary to his primary finding) Abbott does suffer some irreparable harm, that is clearly outweighed by the irreparable harm to Edwards.

The final point of interest is in relation to costs. The parties had incurred substantial costs in preparing evidence as to whether PASCAL is clinically superior to MitraClip. Such evidence would have been relevant had the balance of irreparable harm been even, in which case public interest issues – i.e. the desirability of an allegedly superior product being available – may have been decisive. In the event, given his findings as to likelihood of irreparable harm, the judge did not take the evidence as to clinical superiority into account at all. He ruled whereas Edwards should recover its costs of the application, there should be a deduction for in respect of its costs of the public interest issue. He further cautioned "In my view, parties should think very carefully before setting this ball rolling on an interim application, and I have been told that in this case, the combined costs of this evidence alone, concerning clinical superiority, are in six figures". In our view, it is difficult to criticise Edwards' decision to marshal such evidence. It is not easy to predict the judge's findings as to likelihood of irreparable harm, and a prudent defendant will wish to have a "back up plan", in case the balance of irreparable harm is held to be even. There is an inevitable risk, though, that the cost of preparing evidence for such a fallback argument may end up being irrecoverable if the primary argument is successful.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions